ethyl 3-tetradecylheptadecanoate | 1416474-20-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 3-tetradecylheptadecanoate
• CAS: 1416474-20-8
• 化学式: C₃₃H₆₆O₂
• 分子量: 494.886
• InChiKey: FGWDALNHGKYODS-UHFFFAOYSA-N

物化性质

• 沸点：
  511.7±18.0 °C(Predicted)
• 密度：
  0.857±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.74
• 重原子数：
  35.0
• 可旋转键数：
  29.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  ethyl 3-tetradecylheptadecanoate 在 potassium hydroxide 作用下， 以 水 、 正丁醇 为溶剂， 反应 4.5h， 以99%的产率得到3-tetradecylheptadecanoic acid
  参考文献：
  名称：

  Development of Vizantin, a Safe Immunostimulant, Based on the Structure–Activity Relationship of Trehalose-6,6′-dicorynomycolate

  摘要：

  Vizantin, 6,6'-bis-O-(3-nonyldodecanoy1)-alpha,alpha'-trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6'-dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.

  DOI：

  10.1021/jm3016443
• 作为产物：
  描述：

  15-二十九烷酮 在 platinum(IV) oxide 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 mineral oil 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 41.5h， 生成 ethyl 3-tetradecylheptadecanoate
  参考文献：
  名称：

  Development of Vizantin, a Safe Immunostimulant, Based on the Structure–Activity Relationship of Trehalose-6,6′-dicorynomycolate

  摘要：

  Vizantin, 6,6'-bis-O-(3-nonyldodecanoy1)-alpha,alpha'-trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6'-dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.

  DOI：

  10.1021/jm3016443